Shopping Cart
Remove All
Your shopping cart is currently empty
Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $197 | In Stock | In Stock | |
| 5 mg | $476 | In Stock | In Stock | |
| 10 mg | $787 | - | In Stock | |
| 25 mg | $1,170 | - | In Stock | |
| 50 mg | $1,580 | - | In Stock |
| Description | Abituzumab (DI17E6) is a humanized monoclonal antibody targeting Integrin alphaV, with potential anti-cancer activity. It inhibits phosphorylation of FAK, Akt, and ERK and is used in prostate cancer research. |
| In vitro | Methods: Prostate cancer cell lines were inoculated into 24-well plates and treated with Abituzumab (0.01, 0.1,1,10, 30,100μg/ml). The wound space was measured every 6 hours to observe the invasion and movement of cells. Results: Abituzumab inhibited the movement and invasion of PCa cells. Methods: Prostate cancer cell lines were treated with Abituzumab (100μg/ml) and incubated for 24h. Results: Abituzumab inhibited αV integrin expression and phosphorylation of FAK, Akt and ERK in LNCaP and C4-2B cells. [1] |
| Synonyms | EMD525797, EMD 525797, DI17E6, DI 17E6 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | Integrin aV/ITGAV/CD51 |
| Molecular Weight | 144.58 kDa |
| Cas No. | 1105038-73-0 |
| Color | Transparent |
| Appearance | Liquid |
| Isotype | Human IgG2 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.